Adenocarcinonoma

~90% ^A

Acinar adenocarcinoma (AAC) is the main subtype of prostate cancer. It develops in the cells that line the prostate gland and mostly occurs in men aged over 60.^A,B

Cryoablation has demonstrated excellent outcomes both as a local primary treatment for early-stage prostate cancer and as a strong local
salvage therapy.^{F, G}

Nance M.E, et al. report two successful cases of cryoablation used as salvage therapy for recurrent prostate cancer (adenocarcinoma and squamous cell carcinoma), describing it as a treatment able to provide local tumour control.^H

A recent case study has demonstrated MRI-guided whole-gland cryoablation to be an effective alternative option to treat prostatic adenocarcinoma for patients who had prior pelvic surgery.^I

~5% ^C

Although rare, ductal adenocarcinoma (DAC)  is the second most common subtype of prostatic cancer.^C It develops in the cells that line the ducts (tubes) of the prostate gland and it grows and spreads more quickly than AAC.^A,B  It usually occurs in men aged between 63 and 72.^D

< 5% ^B

(very rare)

Neuroendocrine carcinoma can start in neuroendocrine cells anywhere in the body, rarely in the prostate.^B

Transitional cell cancer usually starts in the urethra or bladder and spreads to the prostate; it can rarely start in the prostate.^E

Small-cell carcinomas accounts for ~1% of prostate cancers. It grows in small round cells in the prostate and can spread very quickly.^E

Squamous cell carcinoma is a rare (<1%) and aggressive form of prostate cancer which develops in the flat cells that cover the prostate glands.^B,E

Soft-tissue prostate cancer is extremely rare (<0.1% of the cases).^B It tends to develop in the soft tissue outside the prostate gland.^E